• Consensus Rating: Moderate Buy
  • Consensus Price Target: $6.19
  • Forecasted Upside: 209.38%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$2.00
▲ +0.02 (1.01%)

This chart shows the closing price for NOTV by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Inotiv Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NOTV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NOTV

Analyst Price Target is $6.19
▲ +209.38% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Inotiv in the last 3 months. The average price target is $6.19, with a high forecast of $10.00 and a low forecast of $2.00. The average price target represents a 209.38% upside from the last price of $2.00.

This chart shows the closing price for NOTV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 4 contributing investment analysts is to moderate buy stock in Inotiv. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/4/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/4/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/2/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/31/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/29/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/27/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/27/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/27/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/16/2024Lake Street CapitalReiterated RatingBuy ➝ Hold$10.00 ➝ $2.00Low
5/16/2024Craig HallumLower TargetBuy ➝ Buy$25.00 ➝ $10.00Low
5/14/2024Jefferies Financial GroupDowngradeBuy ➝ Hold$11.50 ➝ $3.75Low
2/9/2024Jefferies Financial GroupUpgradeHold ➝ Buy$3.00 ➝ $11.50Low
12/12/2023Craig HallumLower TargetBuy ➝ Buy$34.00 ➝ $25.00Low
7/20/2023Wells Fargo & CompanyInitiated CoverageOverweight$9.00Low
1/19/2023Jefferies Financial GroupDowngradeBuy ➝ Hold$8.00Low
1/11/2023Craig HallumLower Target$64.00 ➝ $34.00Low
1/11/2023Lake Street CapitalUpgradeHold ➝ Buy$10.00Low
11/18/2022Lake Street CapitalDowngradeBuy ➝ Hold$60.00 ➝ $7.00Low
10/4/2022Jefferies Financial GroupInitiated CoverageBuy$27.00Low
8/11/2022Lake Street CapitalBoost TargetBuy$50.00 ➝ $60.00Low
6/14/2022Lake Street CapitalLower Target$75.00 ➝ $50.00Low
3/22/2022Colliers SecuritiesReiterated RatingBuyMedium
2/11/2022Lake Street CapitalBoost Target$60.00 ➝ $75.00High
1/31/2022Lake Street CapitalInitiated CoverageBuy$60.00High
12/8/2021Colliers SecuritiesReiterated RatingBuy$71.00Low
9/22/2021Colliers SecuritiesReiterated RatingBuyHigh
9/20/2021Craig HallumInitiated CoverageBuy ➝ Buy$45.00High
8/3/2021Colliers SecuritiesReiterated RatingBuy$36.00Low
7/16/2021Colliers SecuritiesReiterated RatingBuy$36.00Medium
(Data available from 5/27/2019 forward)

News Sentiment Rating

-0.11 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/29/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/28/2023
  • 4 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
12/28/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/27/2024
  • 7 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
2/26/2024
  • 4 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/27/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/26/2024
  • 0 very positive mentions
  • 17 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
5/26/2024

Current Sentiment

  • 0 very positive mentions
  • 17 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Inotiv logo
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company offers research and discovery services, including computational toxicology, disease pharmacology, DMPK, safety pharmacology, discovery bioanalysis, exploratory, surgical models and medical device, and cell and molecular biology; non-clinical safety assessment includes general and genetic toxicology, regulated bioanalysis, carcinogenicity studies, and development and reproductive toxicology; pathology services, such as histology, digital, clinical, and medical device pathology; bioanalysis includes nonregulated discovery bioanalysis, biotherapeutics, and regulated preclinical and clinical bioanalysis; proteomics; and consulting services, as well as model and research services. The company operates in the United States, the Netherlands, and internationally. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.
Read More

Today's Range

Now: $2.00
Low: $1.98
High: $2.08

50 Day Range

MA: $5.84
Low: $1.84
High: $11.04

52 Week Range

Now: $2.00
Low: $1.61
High: $11.42

Volume

174,700 shs

Average Volume

480,533 shs

Market Capitalization

$51.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.37

Frequently Asked Questions

What sell-side analysts currently cover shares of Inotiv?

The following Wall Street analysts have issued research reports on Inotiv in the last year: Craig Hallum, Jefferies Financial Group Inc., Lake Street Capital, and Wells Fargo & Company.
View the latest analyst ratings for NOTV.

What is the current price target for Inotiv?

4 Wall Street analysts have set twelve-month price targets for Inotiv in the last year. Their average twelve-month price target is $6.19, suggesting a possible upside of 209.4%. Craig Hallum has the highest price target set, predicting NOTV will reach $10.00 in the next twelve months. Lake Street Capital has the lowest price target set, forecasting a price of $2.00 for Inotiv in the next year.
View the latest price targets for NOTV.

What is the current consensus analyst rating for Inotiv?

Inotiv currently has 2 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for NOTV.

What other companies compete with Inotiv?

How do I contact Inotiv's investor relations team?

Inotiv's physical mailing address is 2701 KENT AVENUE, WEST LAFAYETTE IN, 47906. The company's listed phone number is (765) 463-4527 and its investor relations email address is [email protected]. The official website for Inotiv is www.inotivco.com. Learn More about contacing Inotiv investor relations.